Oncopeptides AB (publ) (ONCO.ST)
Develops cancer drugs that use peptides to deliver toxic payloads directly into tumor cells.
1.61+0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-72.0%
The outlook
Oncopeptides is trading near its 52-week low, well below both its 50- and 200-day moving averages, signaling a downtrend. Analyst price targets average around 55% above the current price, though coverage leans bearish overall. The stock sits at the bottom of its recent range, reflecting weak near-term momentum.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range7% of the way from its 52-week low to high
Price targetAvg target +55% vs current price
Analyst price target
~12-month · 3 analysts2.50average target+55.3% vs now
Now 1.61
Low 2.10High 3.10
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$614.0M
52-wk high
6.55
52-wk low
1.26
50-day avg
1.69
200-day avg
2.86
Trailing P/E
—